- Previous Close
0.0000 - Open
0.0002 - Bid 0.0012 x --
- Ask 1.0000 x --
- Day's Range
0.0030 - 0.0030 - 52 Week Range
0.0002 - 0.0030 - Volume
300,000 - Avg. Volume
31,003 - Market Cap (intraday)
10.019M - Beta (5Y Monthly) 2.15
- PE Ratio (TTM)
-- - EPS (TTM)
-0.0000 - Earnings Date Mar 6, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Avecho Biotechnology Limited, a biotechnology company, develops and commercializes human and animal health products using its proprietary drug delivery system, tocopherol phosphate mixture (TPM) in Australia, Switzerland, the Americas, and India. It operates through Production and Human Health segments. The company manufactures and sells TPM and Vital ET products for use in drug delivery. Its human health portfolio covers delivery of pharmaceutical products for pain and dermatology applications through gels, injectables, and patches. In addition, the company develops pharmaceutical products; oral, topical, and edible pharmaceutical cannabinoid products, including a cannabidiol TPM soft-gel capsule in Phase III clinical trial for the treatment of insomnia; and non-antibiotic feed additive products to enhance feed efficiency and the health of livestock animals. The company was formerly known as Phosphagenics Limited and changed its name to Avecho Biotechnology Limited in May 2019. Avecho Biotechnology Limited was incorporated in 1992 and is based in Clayton, Australia.
avecho.com.auRecent News: AVEFF
View MorePerformance Overview: AVEFF
Trailing total returns as of 4/7/2025, which may include dividends or other distributions. Benchmark is S&P/ASX 200 [XJO] (^AXJO) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: AVEFF
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: AVEFF
View MoreValuation Measures
Market Cap
10.02M
Enterprise Value
9.20M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
5.47
Price/Book (mrq)
2.17
Enterprise Value/Revenue
11.24
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-275.64%
Return on Assets (ttm)
-31.11%
Return on Equity (ttm)
-64.72%
Revenue (ttm)
1.13M
Net Income Avi to Common (ttm)
-3.12M
Diluted EPS (ttm)
-0.0000
Balance Sheet and Cash Flow
Total Cash (mrq)
2.37M
Total Debt/Equity (mrq)
32.93%
Levered Free Cash Flow (ttm)
-2.85M